Ocular Therapeutix (FRA:0OT) Pretax Margin %: -821.62% (As of Mar. 2026)


FRA:0OT Ocular Therapeutix Inc FRA:0OT
51 GF Score
Price €8.55
GF Value €3.84
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Ocular Therapeutix Pretax Margin %?

Ocular Therapeutix FRA:0OT +2.40% 51 Pretax Margin % is -821.62% as of Mar. 2026. GuruFocus rates FRA:0OT with a GF Score™ of 51/100 and a GF Value™ of €3.84 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 943 Biotechnology companies, Ocular Therapeutix ranks worse than 71.58% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Ocular Therapeutix's Pre-Tax Income for the three months ended in Mar. 2026 was €-76.65 Mil. Ocular Therapeutix's Revenue for the three months ended in Mar. 2026 was €9.33 Mil. Therefore, Ocular Therapeutix's pretax margin for the quarter that ended in Mar. 2026 was -821.62%.

The historical rank and industry rank for Ocular Therapeutix's Pretax Margin % or its related term are showing as below:

FRA:0OT' s Pretax Margin % Range Over the Past 10 Years
Min: -3296.2   Med: -703.11   Max: -15.06
Current: -558.24


FRA:0OT's Pretax Margin % is ranked worse than
71.58% of 943 companies
in the Biotechnology industry
Industry Median: -90.63 vs FRA:0OT: -558.24

Ocular Therapeutix  (FRA:0OT) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Ocular Therapeutix Pretax Margin % Related Terms


Ocular Therapeutix Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Ocular Therapeutix's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocular Therapeutix Pretax Margin % Chart

Ocular Therapeutix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.06 -137.96 -138.15 -303.67 -511.91

Ocular Therapeutix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -598.72 -503.86 -477.31 -487.98 -821.62

FRA:0OT vs NKTR, PVLA, GENB: Pretax Margin % Comparison

For the Biotechnology subindustry, Ocular Therapeutix's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocular Therapeutix Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's Pretax Margin % falls into.


FRA:0OT
51GF Score
Ocular Therapeutix Inc FRA:0OT
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ocular Therapeutix Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Ocular Therapeutix's Pretax Margin for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-227.112/44.366
=-511.91 %

Ocular Therapeutix's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-76.649/9.329
=-821.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of -821.62% mean?
Ocular Therapeutix (FRA:0OT) has a Pretax Margin % of -821.62% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Ocular Therapeutix and its competitors. According to the industry distribution chart, Ocular Therapeutix ranks #675 out of 943 companies in the Biotechnology industry, placing it in the top 71.6%.
Is Ocular Therapeutix's Pretax Margin % too high?
Ocular Therapeutix's current Pretax Margin % is -821.62%. Based on the distribution chart, Ocular Therapeutix ranks #675 out of 943 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ocular Therapeutix has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ocular Therapeutix's Pretax Margin % compare to NKTR and PVLA?
According to the Biotechnology industry distribution chart, Ocular Therapeutix ranks #675 out of 943 companies for Pretax Margin %. This places Ocular Therapeutix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Ocular Therapeutix and its competitors. Ocular Therapeutix's current Pretax Margin % is -821.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocular Therapeutix stock overvalued right now?
Based on GuruFocus' analysis, Ocular Therapeutix (FRA:0OT) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.84, compared to a current price of €8.55 — trading 122.7% above its estimated fair value. The current Pretax Margin % is -821.62%. Ocular Therapeutix's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Ocular Therapeutix (FRA:0OT), the current Pretax Margin % is -821.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ocular Therapeutix (FRA:0OT) Overvalued in 2026?

Based on GuruFocus' analysis, Ocular Therapeutix stock appears to be overvalued. The current stock price of €8.55 is trading 122.7% above its estimated GF Value™ of €3.84. GuruFocus considers Ocular Therapeutix to be Significantly Overvalued.

Key valuation signals for FRA:0OT:

  • Pretax Margin %: -821.62%
  • GF Value™: €3.84 vs. price of €8.55 (122.7% above fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the FRA:0OT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ocular Therapeutix Business Description

Other Exchanges OCUL:USA0OT:Germany
Address 15 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
51GF Score

Get the complete analysis for FRA:0OT

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.55
Price
€3.84
GF Value